Pharmaceuticals News

BOSTON, April 01, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that, on April 1, 2026,...

SAN DIEGO, April 01, 2026 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1...

In 2025, muzastotug showed 29% confirmed overall response rate (ORR) among 21 patients with MSS CRC in the 20 mg/kg dose cohorts Median overall survival (OS) for the 10 mg/kg cohorts was 19.4...

Abivax Publishes Financial Reports with the French and U.S. Securities Regulatory Agencies Abivax publishes financial reports with the French and U.S. securities regulatory agencies PARIS, France –...

HAMPTON, N.J., April 01, 2026 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (“Celldex” or the “Company”) (Nasdaq: CLDX) today announced that it has commenced an underwritten public offering for the...

Company Announcement COPENHAGEN, Denmark; April 1, 2026 – Genmab A/S (Nasdaq: GMAB) - This document discloses the data of the transactions made in Genmab A/S (Nasdaq: GMAB) by managerial employees...

MOUNTAIN VIEW, Calif., April 01, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a life-sciences company developing innovative targeted oncology therapies and...

CALGARY, Alberta, April 01, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company...

Ipsen annonce la mise à disposition de son Document d’enregistrement universel 2025 PARIS, FRANCE, 1er AVRIL 2026 - Ipsen (Euronext : IPN ; ADR : IPSEY) annonce que son Document d’enregistrement...

Ipsen announces the availability of its 2025 Universal Registration Document PARIS, FRANCE, 1 APRIL 2026 - Ipsen (Euronext: IPN; ADR: IPSEY) announced that its 2025 Universal Registration Document...